Mineralys Therapeutics Inc’s filing revealed that its 10% Owner Samsara BioCapital GP, LLC acquired Company’s shares for reported $8.1 million on Mar 13 ’25. In the deal valued at $13.50 per share,600,000 shares were bought. As a result of this transaction, Samsara BioCapital GP, LLC now holds 5,674,916 shares worth roughly $80.7 million.
Then, AKKARAJU SRINIVAS bought 600,000 shares, generating $8,100,000 in total proceeds. Upon buying the shares at $13.50, the Director now owns 5,674,916 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. bought 1,296,296 shares. Mineralys Therapeutics Inc shares valued at $17,499,996 were divested by the Director at a price of $13.50 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 4,280,051 shares, worth roughly $60.86 million.
H.C. Wainwright initiated its Mineralys Therapeutics Inc [MLYS] rating to a Buy in a research note published on July 10, 2024; the price target was $30. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Wells Fargo began covering MLYS with “an Overweight” recommendation on March 07, 2023. Stifel started covering the stock on March 07, 2023. It rated MLYS as “a Buy”.
Price Performance Review of MLYS
On Monday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock fall -0.21% to $14.22. Over the last five days, the stock has lost -4.95%. Mineralys Therapeutics Inc shares have risen nearly 15.52% since the year began. Nevertheless, the stocks have risen 12.95% over the past one year. While a 52-week high of $18.29 was reached on 03/10/25, a 52-week low of $8.24 was recorded on 02/25/25. SMA at 50 days reached $10.59, while 200 days put it at $12.08.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 13.86, which if violated will result in even more drops to 13.50. On the upside, there is a resistance level at 14.52. A further resistance level may holdings at 14.82. The Relative Strength Index (RSI) on the 14-day chart is 66.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.34, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 42.37%. Stochastics %K at 56.59% indicates the stock is a holding.
How much short interest is there in Mineralys Therapeutics Inc?
A steep rise in short interest was recorded in Mineralys Therapeutics Inc stocks on 2025-02-28, growing by 0.15 million shares to a total of 2.01 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 1.86 million shares. There was a rise of 7.5%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 07, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
